Revenue - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended		12 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Dec. 31, 2024	Jun. 30, 2026	Jun. 30, 2025	Dec. 31, 2025	Dec. 31, 2024
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Revenue	$ 507	$ 5,333		$ 1,203	$ 29,786
ANI Pharmaceuticals, Inc. [Member]
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Product rights agreement date				May 17, 2023
Product [Member]
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Revenue	0	0		$ 467	715
Product [Member] \| Ocumension Therapeutics [Member]
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Revenue	0	0		500	0
Product [Member] \| Product Rights Agreement and the Supply Agreement [Member]
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Revenue	0	0		0	600
License and Collaboration Agreement [Member]
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Revenue	507	5,333		646	16,382
License and Collaboration Agreement [Member] \| ANI Pharmaceuticals, Inc. [Member]
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Revenue	100	200		100	400
Royalty Income [Member]
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Revenue	0	0		90	12,689
Royalty Income [Member] \| Ocumension Therapeutics [Member]
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Revenue		0			0
Product Rights Agreement [Member] \| ANI Pharmaceuticals, Inc. [Member]
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Upfront cash payment				$ 75,000
Guaranteed payments			$ 1,875				$ 7,500
Product Rights Agreement [Member] \| ANI Pharmaceuticals, Inc. [Member] \| Maximum [Member]
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Royalties payment period				2028
Royalty payments						$ 70,000
Product Rights Agreement [Member] \| ANI Pharmaceuticals, Inc. [Member] \| Minimum [Member]
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Royalties payment period				2025
Product Rights Agreement [Member] \| Product Rights Agreement and the Supply Agreement [Member]
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Revenue	$ 0	$ 5,100		$ 0	$ 15,900